Clear need to improve NHS screening for new Alzheimer’s drugs – study
There is a “clear and urgent” need to improve NHS screening to work out who may benefit from new Alzheimer’s drugs, according to a study.
Experts found that just 14% of people screened in specialist clinics may end up benefiting from the drugs, but the tests needed to confirm diagnosis of Alzheimer’s – such as fluid biomarker tests or PET scans – are not easily available on the NHS.
A new crop of drugs, lecanemab and donanemab, slow down early stages of the disease
